No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 ...
Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in ...
TriNav Advance is the fourth FDA-cleared PEDD device in TriSalus’s portfolio, joining the TriNav Infusion System and TriNav ...
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 ...
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small ...
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis. In the Asian subgroup, the overall ...
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full ...
This episode makes the case for moving HER2-targeted therapy into the first-line setting. The panel describes how a frontline ...
Martin T, Usmani S, Berdeja JG, et al. Ciltacabtagene autoleucel in patients with heavily pretreated relapsed/refractory multiple myeloma: 5-year follow-up from CARTITUDE-1. Blood. 2024;144 (suppl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results